Lucid Diagnostics (NASDAQ:LUCD) Given “Buy” Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $2.50 price objective on the stock.

A number of other brokerages have also weighed in on LUCD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Wall Street Zen upgraded Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research report on Thursday, March 26th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and an average target price of $3.94.

Lucid Diagnostics Stock Up 2.7%

Shares of LUCD stock opened at $1.15 on Monday. The company has a 50 day moving average price of $1.29 and a 200-day moving average price of $1.18. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80. The firm has a market capitalization of $158.33 million, a PE ratio of -1.20 and a beta of 1.18.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million. Analysts anticipate that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LUCD. Quadrature Capital Ltd purchased a new position in shares of Lucid Diagnostics during the 2nd quarter worth $29,000. Centiva Capital LP purchased a new stake in shares of Lucid Diagnostics in the 3rd quarter worth $25,000. Sprott Inc. bought a new position in Lucid Diagnostics in the 3rd quarter worth $25,000. Cubist Systematic Strategies LLC bought a new position in Lucid Diagnostics in the 1st quarter worth $39,000. Finally, SG Americas Securities LLC purchased a new position in Lucid Diagnostics during the third quarter valued at $26,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.